SNIPR BIOME, a clinical-stage biotech company based in Copenhagen, has raised €35 million in Series B funding to support the development of its CRISPR-based therapies targeting bacterial infections and antimicrobial resistance. The round includes new investments from the Cystic Fibrosis Foundation and Germany’s SPRIN-D, alongside returning investors Lundbeckfonden BioCapital, North-East Family Office, and Wellington Partners. The funding will be used to develop a treatment for airway infections caused by Pseudomonas aeruginosa in people with cystic fibrosis, to advance research aimed at eliminating antibiotic resistance genes, and to continue clinical trials for SNIPR001, a therapy being tested in patients with hematologic cancers.
SNIPR BIOME is a clinical-stage biotechnology company based in Copenhagen, Denmark, focused on the development of CRISPR-based technologies for targeting bacterial infections and antimicrobial resistance. The company’s research centers on using CRISPR-Cas systems to selectively eliminate specific bacterial strains or genes, such as antibiotic resistance elements, while preserving the broader microbiome. Its lead candidate, SNIPR001, is currently in clinical trials for patients with hematologic cancers. SNIPR BIOME collaborates with public and private research institutions and funding bodies, including CARB-X, the Gates Foundation, and SPRIN-D, and holds patents related to CRISPR applications in microbiome targeting.
“This financing marks a pivotal milestone for SNIPR BIOME as we advance the clinical development of SNIPR001 for the prevention of blood stream infections and continue to expand our infectious disease pipeline targeting pathogens of critical importance,” said Christian Grøndahl, Chief Executive Officer and Co-Founder of SNIPR BIOME and he continued: “This support shows the importance of addressing antimicrobial resistance and infectious disease and the unique position of SNIPR BIOME in the development landscape.”
SNIPR BIOME is pioneering a novel use of CRISPR-Cas technology to cause selective, precise and ultra-rapid killing to eradicate target bacteria and remove the antibiotic resistance genes, while leaving the rest of the patient’s microbial community intact. Furthermore, SNIPR technology is utilized to create CRISPR-medicine designed to convert and produce therapeutics selectively within targeted regions of the gastrointestinal tract. SNIPR Biome harnesses the natural bacterial CRISPR-based adaptive immune system in a programmable way to target bacteria based on their specific genomes.
Click to read more funding news.
Read the orginal article: https://arcticstartup.com/snipr-biome-raises-e35m-series-b/
